Find More Contacts for MabVax Therapeutics
Protected Content
CEO, President
Non-Management, Executive Management
4 emails found 1 phone number found
View contacts for MabVax Therapeutics to access new leads and connect with decision-makers.
View All Contacts
  • Contact Email info@mabvax.com
  • Phone Number (858)259-9405

MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer

vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.

Lists Featuring This Company

Closed California Medical Companies
500 Number of Organizations • $11B Total Funding Amount • 977 Number of Investors
United States Companies that Exited (Top 10K)
9,726 Number of Organizations • $2.7T Total Funding Amount • 56,934 Number of Investors
Closed California Companies (Top 10K)
9,934 Number of Organizations • $136.8B Total Funding Amount • 25,444 Number of Investors
TRITON FUNDS LLC Portfolio Companies
44 Number of Organizations • $2.2B Total Funding Amount • 158 Number of Investors

Frequently Asked Questions

Where is MabVax Therapeutics's headquarters? MabVax Therapeutics is located in San Diego, California, United States.Who invested in MabVax Therapeutics? MabVax Therapeutics has 8 investors including TRITON FUNDS LLC and Boehringer Ingelheim.How much funding has MabVax Therapeutics raised to date? MabVax Therapeutics has raised .When was the last funding round for MabVax Therapeutics? MabVax Therapeutics closed its last funding round on Nov 18, 2018 from a Post-IPO Equity round.Who are MabVax Therapeutics's competitors? Alternatives and possible competitors to MabVax Therapeutics may include Ligand PharmaceuticalsAcceleron Pharma, and AVEO Oncology.